CoChat

Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial

van Beers, Cornelis A J, DeVries, J Hans, Kleijer, Susanne J, Smits, Mark M, Geelhoed-Duijvestijn, Petronella H, Kramer, Mark H H, Diamant, Michaela, Snoek, Frank J, Serné, Erik H · 2016 · The Lancet Diabetes & Endocrinology

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

Abstract

Background Patients with type 1 diabetes who have impaired awareness of hypoglycaemia have a three to six times increased risk of severe hypoglycaemia. We aimed to assess whether continuous glucose monitoring (CGM) improves glycaemia and prevents severe hypoglycaemia compared with self-monitoring of blood glucose (SMBG) in this high-risk population. Methods We did a randomised, open-label, crossover trial (IN CONTROL) at two medical centres in the Netherlands. Eligible participants were patients diagnosed with type 1 diabetes according to American Diabetes Association criteria, aged 18-75 years, with impaired awareness of hypoglycaemia as confirmed by a Gold score of at least 4, and treated with either continuous subcutaneous insulin infusion or multiple daily insulin injections and doing at least three SMBG measurements per day. After screening, re-education about diabetes management, and a 6-week run-in phase (to obtain baseline CGM data), we randomly assigned patients (1:1) with a computer-generated allocation sequence (block size of four) to either 16 weeks of CGM followed by 12 weeks of washout and 16 weeks of SMBG, or 16 weeks of SMBG followed by 12 weeks of washout and 16 weeks of CGM (where the SMBG phase was the control). During the CGM phase, patients used a real-time CGM system consisting of a Paradigm Veo system with a MiniLink transmitter and an Enlite glucose sensor (Medtronic, CA, USA). During the SMBG phase, patients were equipped with a masked CGM device, con…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(16)30193-0

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 33 references

Cited by

See all 396

Metadata

Authors
van Beers, C. A. J., DeVries, J. H., Kleijer, S. J., Smits, M. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H. H., Diamant, M., Snoek, F. J., & Serné, E. H.
Affiliations
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
  • Medisch Centrum Haaglanden (NL)
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2016-11
Volume
4
Issue
11
Pages
893-902
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2519559406
Cited by
386
References
34
Citations by year
2026: 18 · 2025: 24 · 2024: 46 · 2023: 38 · 2022: 39 · 2021: 53 · 2020: 40 · 2019: 52 · 2018: 39 · 2017: 32 · 2016: 4
FWCI
42.61
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
  • Eli Lilly and Company
  • AstraZeneca
  • Sanofi
  • Vrije Universiteit Amsterdam
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
continuous glucose monitoring, type 1 diabetes, impaired awareness of hypoglycaemia, severe hypoglycemia, self-monitoring of blood glucose, glycemic control, insulin pump therapy, multiple daily insulin injections, hypoglycemia prevention, real-time glucose monitoring
MeSH terms
Adult, Awareness, Blood Glucose, Diabetes Mellitus, Type 1, Female, Humans, Hypoglycemia, Male, Middle Aged, Blood Glucose Self-Monitoring, Cross-Over Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. https://app.cochat.ai/papers/10.1016/s2213-8587(16)30193-0
The paper
van Beers, C. A. J., DeVries, J. H., Kleijer, S. J., Smits, M. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H. H., Diamant, M., Snoek, F. J., & Serné, E. H. (2016). Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(16)30193-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.